Zobrazeno 1 - 10
of 877
pro vyhledávání: '"Gary H. Lyman"'
Autor:
Douglas B. Johnson, Michael B. Atkins, Cassandra Hennessy, Trisha Wise-Draper, Hannah Heilman, Joy Awosika, Ziad Bakouny, Chris Labaki, Renee Maria Saliby, Clara Hwang, Sunny R. K. Singh, Nino Balanchivadze, Christopher R. Friese, Leslie A. Fecher, James J. Yoon, Brandon Hayes-Lattin, Mehmet A. Bilen, Cecilia A. Castellano, Gary H. Lyman, Lisa Tachiki, Sumit A. Shah, Michael J. Glover, Daniel B. Flora, Elizabeth Wulff-Burchfield, Anup Kasi, Saqib H. Abbasi, Dimitrios Farmakiotis, Kendra Viera, Elizabeth J. Klein, Lisa B. Weissman, Chinmay Jani, Matthew Puc, Catherine C. Fahey, Daniel Y. Reuben, Sanjay Mishra, Alicia Beeghly-Fadiel, Benjamin French, Jeremy L. Warner, COVID-19 and Cancer Consortium
Publikováno v:
BMC Cancer, Vol 23, Iss 1, Pp 1-9 (2023)
Abstract Introduction COVID-19 particularly impacted patients with co-morbid conditions, including cancer. Patients with melanoma have not been specifically studied in large numbers. Here, we sought to identify factors that associated with COVID-19 s
Externí odkaz:
https://doaj.org/article/69fb2be87d9e4455bca96362eb3128f6
Autor:
Kate K. Watabayashi, Ari Bell-Brown, Karma Kreizenbeck, Kathryn Egan, Gary H. Lyman, Dawn L. Hershman, Kathryn B. Arnold, Aasthaa Bansal, William E. Barlow, Sean D. Sullivan, Scott D. Ramsey
Publikováno v:
BMC Health Services Research, Vol 22, Iss 1, Pp 1-9 (2022)
Abstract Background Cancer Care Delivery (CCD) research studies often require practice-level interventions that pose challenges in the clinical trial setting. The SWOG Cancer Research Network (SWOG) conducted S1415CD, one of the first pragmatic clust
Externí odkaz:
https://doaj.org/article/218b102882d045bc8c10198da963e351
Autor:
Despina Michailidou, Tianyu Zhang, Nicole M. Kuderer, Gary H. Lyman, Andreas P. Diamantopoulos, Pavlos Stamatis, Bernard Ng
Publikováno v:
Frontiers in Immunology, Vol 13 (2022)
Giant cell arteritis (GCA) that affects older patients is an independent risk factor for thromboembolic events. The objective of this study was to identify predictive factors for thromboembolic events in patients with GCA and develop quantitative pre
Externí odkaz:
https://doaj.org/article/a1dee889ff1c4d31aae77c5268ebffd7
Autor:
Alok A. Khorana, Nicole M. Kuderer, Keith McCrae, Dejan Milentijevic, Guillaume Germain, François Laliberté, Sean D. MacKnight, Patrick Lefebvre, Gary H. Lyman, Michael B. Streiff
Publikováno v:
Cancer Medicine, Vol 9, Iss 21, Pp 8062-8073 (2020)
Abstract Background The Khorana score (KS) clinical algorithm is used to predict VTE risk in cancer patients. The study objective was to evaluate VTE and survival rates among patients newly diagnosed with cancer and stratified by KS in a real‐world
Externí odkaz:
https://doaj.org/article/6e3e3acb042d48c0b6344f8f70c12a5f
Autor:
Matthew Ventresca, Holger J. Schünemann, Fergus Macbeth, Mike Clarke, Lehana Thabane, Gareth Griffiths, Simon Noble, David Garcia, Maura Marcucci, Alfonso Iorio, Qi Zhou, Mark Crowther, Elie A. Akl, Gary H. Lyman, Viktoria Gloy, Marcello DiNisio, Matthias Briel
Publikováno v:
BMC Medical Research Methodology, Vol 20, Iss 1, Pp 1-18 (2020)
Abstract Background Shifts in data sharing policy have increased researchers’ access to individual participant data (IPD) from clinical studies. Simultaneously the number of IPD meta-analyses (IPDMAs) is increasing. However, rates of data retrieval
Externí odkaz:
https://doaj.org/article/0650f0bba5ab4194bb8f44724b051960
Publikováno v:
Frontiers in Immunology, Vol 12 (2021)
BackgroundSargramostim [recombinant human granulocyte-macrophage colony-stimulating factor (rhu GM-CSF)] was approved by US FDA in 1991 to accelerate bone marrow recovery in diverse settings of bone marrow failure and is designated on the list of FDA
Externí odkaz:
https://doaj.org/article/7672ca5256fd44b3aad228f016966cef
Publikováno v:
Frontiers in Oncology, Vol 11 (2021)
Chemotherapy-induced damage of hematopoietic stem and progenitor cells (HPSCs) often results in myelosuppression that adversely affects patient health and quality of life. Currently, chemotherapy-induced myelosuppression is managed with chemotherapy
Externí odkaz:
https://doaj.org/article/57b7357bb52c4c438749d10bbd35e9e6
Autor:
Derek Weycker, Robin Doroff, Ahuva Hanau, Charles Bowers, Rajesh Belani, David Chandler, Alexander Lonshteyn, Mark Bensink, Gary H. Lyman
Publikováno v:
BMC Cancer, Vol 19, Iss 1, Pp 1-11 (2019)
Abstract Background Febrile neutropenia (FN) is a serious complication of myelosuppressive chemotherapy. Clinical practice guidelines recommend routine prophylactic coverage with granulocyte colony-stimulating factor (G-CSF)—such as pegfilgrastim
Externí odkaz:
https://doaj.org/article/6f502dc328e549b0b73c5ea112ad8eb4
Autor:
Sarah Barger, Sean D. Sullivan, Ari Bell-Brown, Brad Bott, Anne Marie Ciccarella, John Golenski, Mark Gorman, Judy Johnson, Karma Kreizenbeck, Florence Kurttila, Ginny Mason, Jamie Myers, Carole Seigel, James L. Wade, Guneet Walia, Kate Watabayashi, Gary H. Lyman, Scott D. Ramsey
Publikováno v:
BMC Medical Research Methodology, Vol 19, Iss 1, Pp 1-7 (2019)
Abstract Background The Fred Hutchinson Cancer Research Center has engaged an External Stakeholder Advisory Group (ESAG) in the planning and implementation of the TrACER Study (S1415CD), a five-year pragmatic clinical trial assessing the effectivenes
Externí odkaz:
https://doaj.org/article/f17e98e5d91a4c84a1c6ccf2e3ea63c4
Autor:
Rohini K. Hernandez, Sally W. Wade, Adam Reich, Melissa Pirolli, Alexander Liede, Gary H. Lyman
Publikováno v:
BMC Cancer, Vol 18, Iss 1, Pp 1-11 (2018)
Abstract Background Bone metastases commonly occur in conjunction with solid tumors, and are associated with serious bone complications. Population-based estimates of bone metastasis incidence are limited, often based on autopsy data, and may not ref
Externí odkaz:
https://doaj.org/article/7b025d7401184083b5e9ce3b7fd9cb68